<div id="readability-page-1"><div>By Colin Kellaher Boston Scientific has agreed to buy thrombectomy company Penumbra for about $15 billion in cash and stock in a deal that bolsters its cardiovascular portfolio. Boston Scientific on Thursday said the deal values Penumbra at $374 a share, a 19% premium to Wednesday's closing price of $313.43 for the Alameda, Calif., company. The deal, which carries an enterprise value of around $14.5 billion minus Penumbra's roughly $470 million net cash and short-term investments, is slated to close later this year. Boston Scientific said Penumbra stockholders can elect to receive $374 in cash or 3.8721 Boston Scientific shares for each share held, subject to proration so that the total consideration is about 73% cash and 27% stock. Penumbra shares were recently up 14% at $356.99 in premarket trading, while shares of Boston Scientific fell 3.8% to $90.14. The Marlborough, Mass., medical-technology company said it plans to finance the roughly $11 billion cash portion of the deal with cash on hand and new debt, and that it expects to issue about 41 million shares. Boston Scientific said the acquisition offers an opportunity to enter new, fast-growing segments within the vascular space, noting that Penumbra's portfolio includes devices to treat conditions such as pulmonary embolism, stroke, deep vein thrombosis, acute limb ischemia, heart attack and aneurysms. Penumbra's chairman and chief executive, Adam Elsesser, will join Boston Scientific's board and will elect to receive stock in exchange for his nearly 2% Penumbra stake, Boston Scientific said. The company said it expects to maintain strong credit ratings, and that it will still have the flexibility to execute its capital-allocation priorities of further tuck-in deals, followed by opportunistic stock buybacks. Boston Scientific earlier this week said it would buy Valencia Technologies, a medical-technology company focused on treatments for bladder dysfunction, for an undisclosed amount. Write to Colin Kellaher at colin.kellaher@wsj.com (END) Dow Jones Newswires01-15-26 0829ET</div></div>

波士顿科学

波士顿科学已同意以约 150 亿美元的现金和股票收购 Penumbra，增强其心血管产品组合。该交易对 Penumbra 的估值为每股 374 美元，比其前一个收盘价溢价 19%。股东可以选择现金或波士顿科学的股票。此次收购预计将在今年晚些时候完成，波士顿科学将通过现有现金和新债务来融资现金部分。该交易旨在扩展到新的血管领域，Penumbra 的首席执行官将加入波士顿科学的董事会

波士顿科学将以 150 亿美元现金和股票收购 Penumbra -- 第二次更新